Aap Implantate Ag · XETR:AAQ1
Aap Implantate — 8th DVFA Frühjahrskonferenz 2017
18 slides from Aap Implantate's conference presentation, May 8, 2017
Slide 1: aap Implantate AG Corporate Presentation
aap Implantate AG Corporate Presentation 8th DVFA Frühjahrskonferenz Frankfurt am Main, May 8, 2017 Bruke Seyoum Alemu, CEO Marek Hahn, CFO
Slide 2: Safe Harbor Statement
Safe Harbor Statement Our publication may include predictions, estimates or other information that might be considered forward-looking. While these forward-looking statements represent our current judgment on what the future holds, they are subject to risks and uncertainties that could cause actual
Slide 3: Share Buyback
Share Buyback Partial distribution of proceeds from sale of aap Biomaterials aap’s Management Board and Supervisory Board decided today to implement a share buyback within the next months in order to partially distribute proceeds from last year’s sale of aap Biomaterials GmbH to shareholders Bas
Slide 4: aap Company Overview
aap Company Overview German based international MedTech company Development, manufacturing and marketing of trauma products for orthopaedics Listed in Frankfurt, Germany, Prime standard (XETRA: AAQ) Customers are hospitals, distributors and global companies worldwide Sales 2016: EUR 10.5 m
Slide 5: Our Aspiration
Our Aspiration Making trauma treatment better and cost-effective Challenges in trauma Simplify implantation as well as explantation Prevent surgical site infections Avoid second operations Our response to the challenges Address the challenges through innovations and create a sustainable valu
Slide 6: Our Roadmap for Value Creation
Our Roadmap for Value Creation Transformational roadmap Transformation through divestiture Transformation through innovation Divestiture Innovation In the last years we have In the last years we have been executed diverse divestitures to developing exciting platform become a pure player in t
Slide 7: Transformation Through Innovation
Transformation Through Innovation Clear objectives Clear innovation objectives Address unmet needs Enable differentiation Build strong intellectual property portfolio Ensure cost-effective technical feasibility Fulfil key market regulatory approvals Capture decent market size Our core te
Slide 8: Platform Technology – LOQTEQ
Platform Technology – Value based innovation Market Need Innovative Solution Efficient and minimal invasive surgery ✓ Angular stable compression in one step Angular stable locking and compression ✓ High and sustainable stability High stability of screw-plate-connection As few surgical steps as
Slide 9: Platform Technology – Silver Coating
Platform Technology – Silver Coating Value based innovation Unmet Need Innovative Solution Infection prevention for medical devices Surgical Site Infection (SSI) ✓ Prevention of bacterial colonization ✓ Platform technology with broad application Biofilm formed on an TiAl6V4 ✓ Very high efficacy (in
Slide 10: Platform Technology – Magnesium Implants
Platform Technology – Magnesium Implants Value based innovation Unmet Need Innovative Solution Biocompatible and biodegradable metal implants Disadvantages of currently used metallic implants ✓ Bioabsorbable implants Need of second surgery for implant removal ✓ Platform technology with broad appli
Slide 11: LOQTEQ Roadmap
Gaal LOGTEC’- Roadmap Anatomical Plating System Adressing unmet needs in trauma through a strong patent and technology portfolio * Coated magnesium implants ° fos * Bioabsorbable with Loct EX procedures controlled degradation * High antibacterial efficacy ‘* Excellent biocompatibility LOGTERaayemean
Slide 12: Preliminary Sales Q1/2017 and Guidance
Preliminary Sales Q1/2017 and Guidance (in EUR million) Preliminary Sales* Q1/2017 Q1/2016 Change Trauma 2.9 2.2 +30% thereof North America and Europe 2.1 1.8 +16% thereof RoW 0.8 0.4 +87% Other (mainly discontinued activities) 0.2 0.3 -33% Sales 3.1 2.5 +23% *These preliminary results are based on
Slide 13: Financial Figures FY/2016
Financial Figures FY/2016 (in EUR million) Capital Structure FY/2016 FY/2015 Change Total Assets 63.9 54.9 +16% Equity Ratio 86% 73% +18% Value development FY/2016 FY/2015 Change Share of intangible assets in total assets 17% 19% -11% Freshness Index 26% 21% +24% Cash Structure FY/2016 FY/2015 Chang
Slide 14: Accelerated Path to Profitable Growth
Accelerated Path to Profitable Growth aap Trauma aap Silver Accelerated access to level-1 and -2 Coating technology as a catalyst to hospitals through substantial own trauma portfolio portfolio extension; today >90% Co-development projects and indication coverage in mainstream license deals wi
Slide 15: aap – Sum of the Parts
aap – Sum of the Parts aap Trauma aap Silver Strong IP, comprehensive portfolio Technology addresses unmet need Trauma sales 2016: ca. EUR 9 million; Strong IP, leading platform technology strong LOQTEQ® sales growth with CAGR with a wide range of applications 2011-2016 > 60% Valuation: ex
Slide 16: The New aap – Pure Trauma Company
The New aap – Pure Trauma Company Why invest in aap? aap’s Comprehensive IP protected platform technologies Equity Story LOQTEQ® Technology, Silver Coating Technology, Resorbable Coated Magnesium Implants Technology Comprehensive product portfolio CE, FDA and SFDA approved; indication covera
Slide 17: Shareholder Structure
Shareholder Structure (As of 05/04/2017, shareholdings in aap ≥ 3%) High degree of stability with a base of long-term oriented investors No significant changes for almost 1.5 years* Market Cap of approx. EUR 40 million 13.30% Total number of bearer shares: 30,832,156 Ratio Capital Management B
Slide 18: aap Implantate AG contact details
aap Implantate AG Lorenzweg 5 • 12099 Berlin • Germany www.aap.de Fabian Franke Manager Investor Relations Tel.: +49 30 750 19 – 134 Fax: +49 30 750 19 – 290 E-Mail: ir@aap.de IR-app: 18